<DOC>
	<DOCNO>NCT01929057</DOCNO>
	<brief_summary>The purpose study determine response acne patient healthy control patient P. acne bacteria . Half tube blood drawn participant determine whether antibody P. acne bacterium . Anywhere 1 4 skin biopsy acne pimple normal control skin take subject analysis lab determine whether inflammation pimple reduce use anti-P.acnes antibody .</brief_summary>
	<brief_title>Evaluation Role Propionibacterium Acnes Inflammatory Lesions Associated With Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Fits one follow diagnostic group : 1 . Healthy subject active skin disease history skin disease 2 . Diagnosis moderatetosevere truncal acne diagnose clinically confirm use modify Leeds criterion report use topical acne treatment within past 2 week prior enrollment study , report use oral acne treatment past 4 week prior enrollment study 3 . Diagnosis moderatetosevere truncal acne diagnose clinically confirm use modify Leeds criterion use topical acne treatment 2 week prior enrol study , use oral acne treatment 4 week prior enrol study 2 . Age 1860 year 3 . Male female race ethnicity 4 . Subject agree comply study requirement 1 . Subjects severe medical condition ( ) view investigator prohibit participation study 2 . Subject Netherton 's syndrome genodermatoses result defective epidermal barrier 3 . Pregnant nursing female 4 . Immunocompromised subject ( e.g. , lymphoma , HIV/AIDS , WiskottAldrich Syndrome ) , history active malignant disease ( exclude nonmelanoma skin cancer ) determine participant 's medical history . 5 . Subjects history psychiatric disease history alcohol drug abuse would interfere ability comply study protocol 6 . Subjects significant concurrent medical condition ( ) screen view investigator prohibit participation study ( e.g. , severe concurrent allergic disease , condition associate malignancy , condition associate immunosuppression ) 7 . Active viral fungal skin infection target area 8 . Are currently receive lithium within last 4 week . 9 . Ongoing participation investigational drug trial 10 . Use systemic immunosuppressive therapy less four week prior screen . 11 . Subjects diabetes 12 . Injured , broken skin , per investigator , may lead poor wound heal 13 . Subjects allergies anesthetic medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>